April 2015 Br J Cardiol 2015;22:(2) doi:10.5837/bjc.2015.015 Online First
Katie E O’Sullivan, Eoghan T Hurley, Declan Sugrue, John P Hurley
Abstract
Introduction
Figure 1. View at time of implantation demonstrating a newly deployed JenaValveTM in a patient with a Medtronic-Hall disc valve in the mitral position
Transcatheter aortic valve implantation (TAVI) has become standard of care for patients with severe aortic stenosis at prohibitive operative risk for surgical aortic valve replacement (SAVR).1 The first randomised-controlled trial of TAVI stipulated the presence of a mitral valve prosthesis as an exclusion criterion for enrolment in the trial.2 The main reason was concern that dysfunction of the mitral valve prosthesis might arise during TAVI valve deployment.3 Further concerns wer
|
Full text
